Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9419249 | 0.84 | KDM4E (0.41) | GABRA1GABRB2PRKCIESR1ESR2 | |
| SCHEMBL27869261 | 0.83 | PRKCI (0.50) | ADRA2AADRA2BADRA2CADRA1AADRB2 | |
| SCHEMBL18671257 | 0.82 | MEP1A (0.49) | GABRA1GABRB2PRKCIESR1ESR2 | |
| SCHEMBL13326871 | 0.78 | MEP1B (0.51) | GABRA1GABRB2FEN1 | |
| SCHEMBL17997275 | 0.78 | GABRA1 (0.41) | GABRA1GABRB2PRKCIFEN1 | |
| SCHEMBL29719025 | 0.78 | GABRA1 (0.56) | GABRA1GABRB2PRKCIESR1ESR2 | |
| SCHEMBL2475390 | 0.78 | GABRA1 (0.56) | GABRA1GABRB2PRKCIESR1ESR2 | |
| SCHEMBL16637663 | 0.77 | GABRA1 (0.44) | GABRA1GABRB2PRKCIESR1ESR2 | |
| SCHEMBL19196278 | 0.77 | GABRA1 (0.39) | GABRA1GABRB2FEN1 | |
| SCHEMBL10335750 | 0.75 | P2RX7 (0.37) | GABRA1GABRB2ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070774-A1 | PENAM DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | TENNOR THERAPEUTICS LIMITED (CN) | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070774-A1 | PENAM DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | BPGM, BLVRB, PREP | GABRA1 4305/4885GABRB2 3643/4885ADRA2A 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.